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A bs tr ac t
Background
Tibolone has estrogenic, progestogenic, and androgenic effects. Although tibolone 
prevents bone loss, its effects on fractures, breast cancer, and cardiovascular disease 
are uncertain.
Methods
In this randomized study, we assigned 4538 women, who were between the ages of 
60 and 85 years and had a bone mineral density T score of −2.5 or less at the hip or 
spine or a T score of −2.0 or less and radiologic evidence of a vertebral fracture, to 
receive once-daily tibolone (at a dose of 1.25 mg) or placebo. Annual spine radio-
graphs were used to assess for vertebral fracture. Rates of cardiovascular events and 
breast cancer were adjudicated by expert panels.
Results
During a median of 34 months of treatment, the tibolone group, as compared with 
the placebo group, had a decreased risk of vertebral fracture, with 70 cases versus 
126 cases per 1000 person-years (relative hazard, 0.55; 95% confidence interval [CI], 
0.41 to 0.74; P<0.001), and a decreased risk of nonvertebral fracture, with 122 cases 
versus 166 cases per 1000 person-years (relative hazard, 0.74; 95% CI, 0.58 to 0.93; 
P = 0.01). The tibolone group also had a decreased risk of invasive breast cancer 
(relative hazard, 0.32; 95% CI, 0.13 to 0.80; P = 0.02) and colon cancer (relative haz-
ard, 0.31; 95% CI, 0.10 to 0.96; P=0.04). However, the tibolone group had an in-
creased risk of stroke (relative hazard, 2.19; 95% CI, 1.14 to 4.23; P = 0.02), for which 
the study was stopped in February 2006 at the recommendation of the data and 
safety monitoring board. There were no significant differences in the risk of either 
coronary heart disease or venous thromboembolism between the two groups.
Conclusions
Tibolone reduced the risk of fracture and breast cancer and possibly colon cancer 
but increased the risk of stroke in older women with osteoporosis. (ClinicalTrials.
gov number, NCT00519857.)
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Tibolone is approved in 90 countries to treat menopausal symptoms and in 45 countries to prevent osteoporosis. Tibolone 
metabolites have estrogenic, progestogenic, and 
androgenic activities.1-3 Tibolone preserves bone 
mineral density,4-6 reduces hot flushes,7-9 and may 
increase libido and vaginal lubrication.10,11 Tibo-
lone treatment has little effect on levels of low-
density-lipoprotein cholesterol but decreases lev-
els of high-density-lipoprotein (HDL) cholesterol 
and triglycerides.5,12 Our study, called the Long-
Term Intervention on Fractures with Tibolone 
(LIFT), tested the primary hypothesis that treat-
ment with tibolone reduces the risk of vertebral 
fracture and, secondarily, modifies the risks of 
nonvertebral fracture, breast cancer, deep-vein 




In this randomized, double-blind, placebo-con-
trolled clinical trial, we examined the effect of 
1.25 mg of tibolone daily on the risk of vertebral 
and clinical fractures after 3 years and planned 
to assess the risks of breast cancer, cardiovascu-
lar disease, and endometrial cancer after 5 years.
From July 2001 to June 2003, we recruited 
women between the ages of 60 and 85 years who 
had a bone mineral density T score of −2.5 or less 
at the hip or lumbar spine or a T score of −2.0 or 
less with radiologic evidence of a vertebral frac-
ture. Women with more than two vertebral frac-
tures, a T score of less than −4.0 at the hip or 
spine, or a clinical diagnosis of vertebral fracture 
in the past year were excluded. Other criteria for 
exclusion were cancer (other than nonmelanoma 
skin cancer) within the past 5 years, previous 
thromboembolic disease, mammographic results 
with a suspicion of cancer, the use of estrogen dur-
ing the previous 3 months, current use of ralox-
ifene or tamoxifen, the use of a bisphosphonate 
for at least 1 month during the previous year, or 
a body-mass index (the weight in kilograms di-
vided by the square of the height in meters) of 
more than 34. Women with a uterus underwent 
transvaginal ultrasonography, and the finding of 
a double-layer endometrial thickness of more than 
4 mm was a reason for exclusion.
Patients were randomly assigned to receive 
either 1.25 mg of tibolone or an identical placebo 
daily. All patients received two to four tablets of 
calcium with vitamin D (315 mg of calcium citrate 
plus 200 IU of vitamin D3) daily. Patients who 
discontinued a study drug were allowed to con-
tinue with follow-up assessments and were in-
cluded in the intention-to-treat analyses.
Assessment of Baseline Vertebral Fractures
A radiologist at the reading center (Synarc) grad-
ed vertebrae semiquantitatively on the severity of 
deformity as none (grade 0), mild (grade 1, a 20 
to 25% reduction in vertebral height), moderate 
(grade 2, >25 to 40% reduction), or severe (grade 3, 
>40% reduction).13 A second radiologist qualita-
tively assessed whether a fracture was present (bi-
nary semiquantitative grading) and assessed ver-
tebral dimensions (quantitative morphometry). A 
vertebral fracture was diagnosed if there was 
agreement in two assessments.14
Outcome Assessment
Incident fractures were defined as a change from 
grade 0 to at least grade 1, as confirmed either by 
the presence of a fracture as seen clearly by the 
radiologist (binary semiquantitative grading) or 
by a decrease in vertebral height of 20% or more 
and 4 mm or more. Patients’ reports of nonverte-
bral fractures were confirmed by written reports 
from a radiologist or an orthopedic surgeon. Patho-
logic fractures, those attributed by the investigator 
to excessive trauma, and those unrelated to low 
bone mineral density (i.e., fractures of the face, 
skull, toe, or finger15) were excluded.
Dual-energy x-ray absorptiometry scans of the 
lumbar spine and proximal femur, which were 
performed by Lunar or Hologic densitometers, 
were analyzed centrally (Synarc). If bone mineral 
density at the hip or spine decreased by 7% or 
more from baseline or between visits, as con-
firmed by a repeat scan, study treatment was 
stopped, and the patient was advised about other 
approved therapies for osteoporosis.
Mammograms were repeated either annually 
at sites in which local guidelines recommended 
annual mammography or after 3 years at sites in 
which local guidelines did not recommend peri-
odic mammography. Patients in each group under-
went an average of 3.5 mammograms, including 
the baseline imaging. The local study physician 
managed follow-up of abnormal results; breast 
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cancer was confirmed from pathological reports 
by consensus of the Breast and Gynecological 
Cancer Adjudication Committee.
Women with a uterus underwent annual trans-
vaginal ultrasonography, and it was recommend-
ed that patients in whom a double-layer endome-
trial thickness of more than 4 mm developed 
should undergo endometrial biopsy (Pipelle, 
Prodimed) if feasible. Women with persistent, se-
vere vaginal bleeding during the first 3 months, 
persistent bleeding during the first 6 months, or 
frequent bleeding at any other time were also ad-
vised to undergo endometrial biopsy; slides were 
read by two gynecologic pathologists, and a third 
pathologist resolved disagreements.16 Cervical cy-
tologic smears were performed annually in pa-
tients with a cervix.
A committee of cardiologists and a neurologist 
defined terms from the Medical Dictionary for Regu-
latory Activities that might be cardiovascular out-
comes of the trial, and such potential events and 
causes of death were adjudicated by prospectively 
defined criteria. Strokes were diagnosed and clas-
sified on the basis of computed tomography or 
magnetic resonance imaging or on the basis of 
typical neurologic findings lasting longer than 
24 hours.
Weight was measured every 6 months. Blood 
tests that were performed at either 36 months or 
the end of the study included measurements of 
liver function.
Study Design
The study was approved by institutional review 
boards at 80 sites in 22 countries. Ten sites in the 
United States discontinued the trial in January 2003 
after assigning 41 women to receive tibolone and 
36 women to receive placebo because the central 
review board at each site changed its rules regard-
ing placebo-controlled osteoporosis trials; those 
patients are included in the intention-to-treat 
analyses.
The data and safety monitoring committee 
reviewed unblinded data at least every 6 months. 
The committee prospectively established stopping 
boundaries for the primary end point (vertebral 
fracture) according to the Lan–DeMets procedure 
with a symmetric 0.05-level, two-sided O’Brien–
Fleming spending function.17 The committee con-
sidered continuation of the study on the basis of 
a balance of risks and benefits.
A steering committee whose members were not 
employed by the sponsor, Organon, oversaw the 
design and conduct of the trial and unanimous-
ly approved the decision to publish the results. 
The study sponsor held the data, and all analyses 
were performed by a statistician employed by the 
sponsor. The authors had access to the data and 
the analyses. Results for primary and secondary 
outcomes were independently confirmed by an 
analyst at the San Francisco Coordinating Center. 
All authors vouch for the accuracy and complete-
ness of the acquired data and reported results.
Statistical Analysis
In determining that 4000 patients were needed for 
the study, we assumed that 20% of the patients 
would already have had a vertebral fracture at base-
line and that the annual rate of vertebral fracture 
in the placebo group would be 6% in those with 
a vertebral fracture and 1.4% in those without a 
vertebral fracture. The study had a power of 90% 
to detect a 40% reduction in the risk of new ver-
tebral fracture at 3 years. 
Analyses generally included all women who 
had undergone randomization and had received 
at least one dose of a study drug (2249 in the 
tibolone group and 2257 in the placebo group), 
except as noted. Analyses of fractures included 
patients with at least one follow-up radiograph 
(2059 in the tibolone group and 2087 in the pla-
cebo group). Outcomes were analyzed with the use 
of Cox regression models, and results are reported 
as relative hazards with 95% confidence intervals. 
We used Poisson regression models to analyze dif-
ferences in absolute rates. Analyses of potential 
interactions were prespecified and limited to the 
effect on fractures in subgroups, according to the 
presence of a vertebral fracture at baseline, and 
the effects on stroke, according to age group and 
the duration of treatment. The significance was 
tested according to treatment-by-stratum interac-
tions in Cox models.
R esult s
Patients
A total of 4538 patients were randomly assigned 
to receive either 1.25 mg of tibolone or an indistin-
guishable placebo once daily. Of these patients, 
4534 underwent randomization with use of an in-
teractive voice-response system. Another four pa-
tients underwent randomization without the se-
quence specified by the voice-response system; 
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these patients were included in the as-treated group, 
since they each received a study drug. About 40% 
of the patients were 70 years of age or older, and 
26% had already had a vertebral fracture (Table 1).
In October 2005, the data and safety monitor-
ing board notified the sponsor about a potential 
increased risk of stroke in the tibolone group; the 
sponsor notified the patients, and 496 women 
discontinued a study drug. In February 2006, the 
committee recommended stopping the trial be-
cause of an increased risk of stroke and because 
the effect of treatment on the risk of vertebral 
fracture met the formal criteria for stopping the 
trial for efficacy. During a median of 34 months 
of treatment, 91% of the patients had received at 
least 80% of the scheduled doses of a prescribed 
study drug.
Fractures and Bone Density
As compared with the placebo group, the tibolone 
group had an increase in bone mineral density of 
4.8 percentage points (95% confidence interval 
[CI], 4.5 to 5.2) in the spine and of 3.1 percentage 
points (95% CI, 2.7 to 3.4) in the femoral neck 
(Fig. 1A). In the tibolone group, there was a re-
duction in the absolute risk of vertebral fracture 
of 8.6 (95% CI, 4.4 to 12.9) per 1000 person-years 
and a reduction in the relative hazard of 45% 
(95% CI, 26 to 59) (Table 2). There was also a 
reduction in the absolute risk of nonvertebral frac-
ture of 6.9 (95% CI, 1.6 to 12.2) per 1000 person-
years and a reduction in the relative hazard by 
26% (95% CI, 7 to 42) (Table 2 and Fig. 1B). In 
the tibolone group, there was a reduction in the 
absolute risk of wrist fracture of 4.4 per 1000 
person-years (95% CI, 1.5 to 7.4) and a reduction 
in the relative hazard by 46% (95% CI, 18 to 65). 
Hip fracture occurred in 10 patients in the tibo-
lone group and in 14 in the placebo group (rela-
tive hazard, 0.72; 95% CI, 0.32 to 1.63).
Women who had already had a vertebral frac-
ture at baseline had higher rates of vertebral and 
nonvertebral fractures; therefore, tibolone appeared 
to reduce the absolute risk of these fractures more 
for women who had already had a vertebral frac-
ture than in those who had not had such a frac-
ture (Table 3). Among women who had already had 
a vertebral fracture at baseline, tibolone was as-
sociated with a decrease in the absolute risk of 
vertebral fracture of 20.8 per 1000 person-years 
and with a decrease in the relative hazard of 61%. 
In these women, tibolone reduced the absolute risk 
of nonvertebral fracture by 17.7 per 1000 person-
years and the relative hazard by 47% (Table 3). 
In contrast, among women who had not had a 
vertebral fracture at baseline, tibolone was as-
sociated with a reduction in the absolute risk of 
vertebral fracture of 4.6 per 1000 person-years 
and a reduction in the relative hazard of 31%; it 
was associated with a reduction in the absolute 
risk of nonvertebral fracture of 3.2 per 1000 per-
son-years and a reduction in the relative hazard of 
14% (P = 0.07 for both interactions).
Breast and Colon Cancer
In the tibolone group, there was a decrease in the 
absolute incidence of invasive breast cancer of 1.9 
(95% CI, 0.5 to 3.4) per 1000 person-years and a 
decrease in the relative risk of 68% (95% CI, 20 
to 87), as compared with the placebo group (Ta-
ble 2 and Fig. 2A). One case of ductal carcinoma 
in situ was also diagnosed in each group. In the 
tibolone group, there was a decrease in the abso-







Mean — yr 68.3±5.2 68.2±5.2
≤69 yr — no. (%) 1352 (60) 1349 (60)
≥70 yr — no. (%) 915 (40) 918 (40)
Body-mass index 25.7±3.4 25.7±3.4
Previous hormone therapy — no. (%) 482 (21) 461 (20)
Family history of breast cancer — no. (%)† 208 (9) 223 (10)
Current smoker — no. (%) 289 (13) 254 (11)
Hypertension — no. (%) 807 (36) 806 (36)
Diabetes — no. (%) 106 (5) 115 (5)
Prevalent vertebral fracture — no. (%) 607 (27) 584 (26)
Previous nonvertebral fracture — no. (%) 528 (23) 479 (21)
Bone mineral density T score‡
Total hip −1.8±0.78 −1.8±0.79
Lumbar spine −2.9±0.61 −2.9±0.55
Intact uterus — no. (%) 1746 (77) 1773 (78)
* Plus–minus values are means ±SD. The total numbers of patients in each 
group include all those who underwent randomization with the use of an in-
teractive voice-response system, although 18 patients in the tibolone group 
and 10 in the placebo group did not receive a study drug. The body-mass in-
dex is the weight in kilograms divided by the square of the height in meters. 
† Patients had a history of breast cancer in a first-degree female relative.
‡ Measurements of bone mineral density that were obtained with the use of 
Lunar and Hologic densitometers were standardized for comparability.
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lute incidence of colon cancer of 1.3 (95% CI, 0.1 
to 2.6) per 1000 person-years and a decrease in the 
relative hazard of 69% (95% CI, 4 to 90), as com-
pared with the placebo group (Table 2). There 
were no significant differences in the risk of other 
types of cancers.
Cardiovascular and Cerebrovascular Disease
Women in the tibolone group had an increase in 
the absolute risk of stroke of 2.3 (95% CI, 0.4 to 
4.2) per 1000 person-years and an increase in the 
relative hazard of 2.19 (95% CI, 1.14 to 4.23) (Ta-
ble 2 and Fig. 2B). Among patients 70 years of 
age or older, the risk of stroke was 6.6 per 1000 
person-years in the tibolone group and 3.4 per 
1000 person-years in the placebo group (differ-
ence in absolute risk, 3.1 per 1000 person-years); 
among those between the ages of 60 and 69 years, 
the risks were 2.8 and 1.0 per 1000 person-years, 
respectively (difference in absolute risk, 1.8 per 
1000 person-years). The increased risk of stroke 
appeared to be greater in the first year (relative 
hazard, 4.1) than in later years (relative hazard, 
1.6), but the treatment-by-time interaction was 
not significant (P = 0.23). Transient ischemic at-
tacks were rare in both the tibolone group (0.3%) 
and the placebo group (0.2%). The two groups did 
not differ significantly in rates of venous throm-
boembolism or coronary heart disease events 
(Table 2).
Gynecologic Outcomes
Among study patients who had a uterus, endo-
metrial cancer was diagnosed in 4 of 1746 wom-
en in the tibolone group (0.8 per 1000 person-years) 
and in none of 1773 patients in the placebo group 
(P = 0.06). Vaginal bleeding was reported as an 
adverse event by 9.5% of women in the tibolone 
group and 2.5% in the placebo group. At some 
point in the trial, 533 women in the tibolone group 
and 168 in the placebo group were found to have 
an endometrial thickness of more than 4 mm, as 
seen on ultrasonography. For bleeding or increased 
endometrial thickness, 499 women in the tibo-
lone group and 136 in the placebo group under-
went endometrial biopsy. Endometrial hyperplasia 
was diagnosed in two women in the tibolone group 
and one woman in the placebo group.
Of women who had a cervix and underwent 
at least one cervical cytologic smear, 132 of 1746 








































AUTHOR, PLEASE NOTE: 
















































Figure 1. Percent Changes in Bone Mineral Density  
and Cumulative Proportions of Patients with Nonverte-
bral Fractures.
Panel A shows the percent changes in bone mineral 
density at the lumbar spine and femoral neck in the 
two study groups after 4 years. The differences be-
tween the tibolone group and the placebo group were 
significant (P<0.001) at each year. The I bars denote 
95% confidence intervals. Panel B shows the cumula-
tive proportions of patients in the two groups with 
nonvertebral fractures (relative hazard in the tibolone 
group, 0.75; 95% CI, 0.58 to 0.93). 
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1773 patients (3.2%) in the placebo group had mild 
dysplasia or atypical cells of unknown significance 
on cytologic analysis (P = 0.009); there was no sig-
nificant difference in the incidence of moderate 
or severe dysplasia (0.4% vs. 0.3%), and only one 
case of cervical cancer occurred in each group. 
Hysterectomies were performed in 18 women (1.0%) 
in the tibolone group and in 15 (0.8%) in the pla-
cebo group.
Other Effects
More patients in the tibolone group than in the 
placebo group discontinued treatment because of 
an adverse event, most commonly vaginal dis-
charge, vaginal bleeding, or breast discomfort (Ta-
ble 4). As compared with placebo, tibolone was as-
sociated with a mean increase in weight of 0.6 kg; 
109 of 2050 women (5.3%) in the tibolone group 
and 81 of 2121 (3.8%) in the placebo group gained 
at least 10% of their baseline weight. Liver-func-
tion tests at baseline and at 36 months of follow-
up (in 1312 patients in the tibolone group and 
1368 in the placebo group) revealed that serum 
γ-glutamyltransferase levels increased by a mean 
of 9.9 IU per liter (median, 4.5) in women receiv-
ing tibolone and by 0.9 IU per liter (median, 1.0) 
in those receiving placebo (P<0.001); 60 women 
(4.6%) in the tibolone group and 20 (1.5%) in the 
placebo group had levels of at least 96 IU per liter 
(≥3 times the upper limit of the normal range 
[ULN], P<0.001). Increases in alanine aminotrans-
ferase levels of more than 90 IU per liter (≥3 times 
the ULN) occurred in 12 women (0.9%) in the 
tibolone group and 3 (0.2%) in the placebo group 
(P = 0.02). There was no significant difference in 
serum bilirubin levels between the two groups. 
Only one woman in the tibolone group and 14 in 
the placebo group stopped treatment because of 
bone loss at the hip or spine exceeding 7%, as com-
pared with baseline.
The number of women who reported having 
fallen was 25% less in the tibolone group than in 
the placebo group. There were also fewer reports 
of gastroenteritis and sinus bradycardia in the 
tibolone group.
Discussion
Tibolone was associated with a reduction in the 
risk of vertebral fracture in older women with 
osteoporosis. The absolute reduction was greater 
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had already had a vertebral fracture than among 
those who had not had such a fracture (4.6 per 
1000 person-years). The magnitude of the reduc-
tion in relative risk was similar to those observed 
for therapy with estrogen, bisphosphonates, and 
raloxifene.18 Tibolone was also associated with a 
reduction in the risk of nonvertebral fracture, an 
improvement that was also greater in women 
who had already had a vertebral fracture. A simi-
larly decreased risk of nonvertebral fracture has 
been demonstrated for estrogen therapy19,20 but 
not for the selective estrogen-receptor modulators 
(SERMs) raloxifene and tamoxifen.21-23
Tibolone was associated with a reduction in the 
risk of invasive breast cancer to a degree that was 
similar to that observed for treatment with tamox-
ifen or raloxifene.24-26 Estrogen-receptor status was 
not available for the study patients, but tibolone 
was probably associated with a decreased risk of 
estrogen-receptor–positive disease because it is by 
far the most common type in this age group.27
The observational Million Women Study re-
ported that the use of tibolone for up to 5 years 
was associated with an increased risk of breast 
cancer, as compared with nonuse of hormone 
therapy (relative risk, 1.21; 95% CI, 1.07 to 1.37).28 
In contrast, a large case–control study, also con-
ducted in the United Kingdom, showed no in-
creased risk of breast cancer (relative risk, 0.86; 
95% CI, 0.65 to 1.13) with an average of 6.5 years 
of use of tibolone.29 It is not clear why the results 
of these observational studies differ from the re-
duced risk that we report. If tibolone were pre-
scribed instead of estrogen therapy for women at 
increased risk of breast cancer, this would spuri-
ously increase the risk of breast cancer associated 
with tibolone. However, risk factors for breast can-
cer were similar in women taking tibolone and 
estrogen therapies in the Million Women Study.28
It is not clear how tibolone would decrease the 
risk of breast cancer. Tibolone appears to stimu-
late proliferation of human MCF-7 cells,30 albeit 
less than estradiol does.31,32 Other studies have 
shown that tibolone decreases the proliferation 
of breast epithelial cells and causes apoptosis of 
breast-cancer cells.33-35 Tibolone might decrease 
the intracellular production of estradiol by inhib-
iting aromatase,36 and it might inhibit sulfatase 
and stimulate sulfotransferase activities, thereby 
increasing circulating levels of the weak or inac-
tive sulfated forms of estrogen that might com-


































































































































































































































































































































































































































































































The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF ADELAIDE LIBRARY on April 30, 2014. For personal use only. No other uses without permission. 
 Copyright © 2008 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 359;7 www.nejm.org august 14, 2008704
The increased risk of stroke with tibolone has 
also been reported with estrogen therapy,20,39 but 
the biologic mechanism is not certain. A random-
ized, placebo-controlled trial showed that 2.5 mg 
of tibolone and conjugated equine estrogen plus 
medroxyprogesterone slightly increased the in-
tima–media thickness by 0.004 mm per year.40 
Tibolone increases levels of C-reactive protein, a 
risk factor for stroke, to a degree similar to that 
of conjugated equine estrogen.41 In randomized 
trials, tibolone decreased HDL cholesterol levels 
but improved lipoprotein(a) levels, did not signifi-
cantly change homocysteine levels, and increased 
plasminogen levels.41,42 Treatment with tibolone 
had no effect on blood pressure or fasting blood 
glucose levels.40
Since the risk of stroke rises exponentially with 
age, tibolone should generally not be used in el-
derly women. Tibolone has been used by women 
between the ages of 50 and 60 years for meno-
pausal symptoms and the prevention of osteopo-
rosis when the risk of stroke was low, but it 
should be avoided in women who have strong 
risk factors for stroke, such as hypertension, smok-
ing, diabetes, and atrial fibrillation.43 Although the 
overall number of adverse events was small, there 
was no increased risk of venous thromboembo-
lism, as has been seen with hormone therapy and 
SERMs, or an increased risk of coronary events, 
as has been seen with conjugated estrogen com-
bined with medroxyprogestrone.21,23,39
With respect to the four women in the tibolone 
group in whom endometrial cancer developed, 
the Million Women Study reported an association 
between the use of tibolone and an increased risk 
of endometrial cancer.44 In a 2-year randomized 
trial of 2.5 mg of tibolone daily involving 1598 
women who were younger (mean age, 54 years) 
than the patients in our study (mean age, 68 years), 
no cases of endometrial cancer occurred.45 We 
found that women in the tibolone group were 
three times as likely to report vaginal bleeding 
and have an endometrial thickness of more than 
4 mm (leading to an increase in the rate of en-
dometrial biopsy by a factor of 3) as were those 
in the placebo group.46 The increased surveillance 
might account, at least in part, for the increased 
diagnosis of endometrial cancer.46 There was no 
difference between the two groups in the low 
rate of endometrial hyperplasia. Although tibolone 
might increase the risk of endometrial cancer, the 
absolute risk was small during 3 years of therapy. 
There was a slight increase in reports of pelvic 
pain, as was seen in a previous trial of tibolone, 
but the cause was not clear.7
Treatment with tibolone was associated with 
several gynecologic symptoms that have also been 
observed with postmenopausal hormone therapy, 
including vaginal bleeding, vaginal discharge, and 
breast discomfort. The increased rate of minimally 
abnormal cervical cytologic results in the tibolone 
group was also seen with conjugated equine estro-
gens plus medroxyprogesterone in the Heart and 
Estrogen/Progestin Replacement Study (HERS)47 
and the Women’s Health Initiative (WHI) study48; 
the cause of this effect is not known. 
The incidence of colon cancer was not a pre-
specified trial outcome, and the number of cases 
was small. Nevertheless, the decreased rate of co-
lon cancer in the tibolone group, as compared with 
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Figure 2. Cumulative Percentages of Patients with Breast Cancer  
and Stroke.
At 4 years, therapy with tibolone was associated with a decrease in the risk 
of invasive breast cancer (relative hazard, 0.32; 95% CI, 0.13 to 0.80; 
P = 0.02) (Panel A) but with an increase in the risk of stroke (relative hazard, 
2.19; 95% CI, 1.14 to 4.23; P=0.02) (Panel B). 
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risk of colon cancer associated with the combi-
nation of estrogen and progestin49 but not estro-
gen alone20 in the WHI study. Potential mecha-
nisms for an effect of estrogen include decreased 
production of potentially carcinogenic bile acids, 
decreased proliferation of intestinal epithelial cells, 
and reduced levels of insulin and insulin-like 
growth factor 1.49
Treatment with tibolone occasionally increased 
γ-glutamyltransferase levels, typical of intrahe-
patic nonalcoholic steatohepatitis, an uncommon 
effect of estrogen therapy that generally resolves 
when treatment stops.50 This effect has not pre-
viously been reported with tibolone. Because fol-
low-up liver-function tests were obtained only at 
36 months, the time course of this effect is not 
known.
Previous trials reported that tibolone increased 
weight by increasing lean body mass or water.51 
A small trial suggested that tibolone might in-
crease grip and leg-extensor strength.8 Thus, the 
lower rate of falling in the tibolone group, re-
ported as an adverse event, might reflect an an-
drogenic effect on muscular function. It has been 
observed that among older men, higher levels of 
testosterone have been associated with lower rates 
of falling.52 In contrast, estrogen therapy does not 
reduce the risk of falling.53
Our study adjudicated incident fractures, breast 
cancer, cardiovascular events, and the endometrial 
effects of tibolone. However, the study had lim-
ited power to analyze other important outcomes, 
such as coronary heart disease and endometrial 
cancer. Since the study lasted for a mean of 3 years, 
the profile of risks and benefits might change with 
longer treatment. For example, although not sig-





(N = 2257) P Value
no. of events (%)
Death 26 (1.2) 28 (1.2) 0.89
Serious event† 548 (24.4) 517 (22.9) 0.26
Any event 2098 (93.3) 2067 (91.6) 0.03
Gynecologic event‡
Vaginal discharge 221 (9.8) 40 (1.8) <0.001
Breast discomfort 203 (9.0) 65 (2.9) <0.001
Vaginal bleeding§ 165 (9.5) 45 (2.5) <0.001
Vaginal infection 186 (8.3) 56 (2.5) <0.001
Pelvic pain 53 (2.4) 29 (1.3) 0.007
Other event‡
Falling 154 (6.8) 205 (9.1) 0.006
Gastroenteritis 57 (2.5) 87 (3.9) 0.01
Sinus bradycardia 33 (1.5) 52 (2.3) 0.008
Discontinued treatment owing to adverse event 422 (18.8) 296 (13.1) <0.001
Reason for discontinuation
Vaginal bleeding§ 31 (1.8) 7 (0.4) <0.001
Increased endometrial thickness 26 (1.2) 6 (0.3) <0.001
Breast discomfort 25 (1.1) 4 (0.2) <0.001
Vaginal discharge 24 (1.1) 2 (0.1) <0.001
* The analysis includes all patients who received at least one dose of a study drug. Patients could have more than one 
adverse event.
† Serious adverse events were all deaths, life-threatening events, hospitalizations, and other events that caused disability or 
prompted intervention to prevent permanent impairment. Such events included cardiovascular events, breast cancer, en-
dometrial cancer, and other events that were adjudicated in a blinded fashion and are reported in the text and in Figure 2.
‡ Other adverse events were included if they occurred in at least 2% of either group (P≤0.01).
§ The percentages are based on the number of patients who had a uterus (1746 in the tibolone group and 1773 in the 
placebo group). 
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nificant, the risk of stroke appeared to decrease 
with time. On the other hand, the influence of 
tibolone on the risk of endometrial cancer might 
increase with time.
Racial or ethnic background and dose are fac-
tors to consider when interpreting these data. The 
study was an international trial, but few patients 
were black or Asian. We examined the effects of 
1.25 mg of tibolone daily, but 2.5 mg is used for 
vasomotor symptoms. Previous studies have found 
that 2.5 mg of tibolone had only a slightly greater 
effect than 1.25 mg on bone density, markers of 
bone resorption, and lipid levels.4,5,12
We conclude that among older women with 
osteoporosis, tibolone decreased the risk of ver-
tebral and nonvertebral fractures, particularly in 
patients who had already had a vertebral fracture. 
It was associated with a decreased risk of breast 
cancer and perhaps colon cancer. However, it was 
associated with an increased risk of stroke and 
therefore should not be used in elderly women 
and women with risk factors for stroke. Tibolone 
had other effects resembling those of therapy 
combining estrogen and progestin. In instances 
in which tibolone is approved for use, these po-
tential risks and benefits and other effects should 
be weighed when considering the use of tibolone 
for the treatment of menopausal symptoms or frac-
ture prevention.
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